Left ventricular assist devices: An evolving state of the art

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 14, Issue 1, 2010, Pages 21-23

  Leff, Jonathan D ^a   Shore Lesserson, Linda ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Axial flow devices; Congestive heart failure (CHF); Left ventricular assist device (LVAD); Magnetic levitation devices; Pulsatile flow devices

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; ASSISTED CIRCULATION; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; SURVIVAL; BIVENTRICULAR ASSIST DEVICE; BRIDGE TO TRANSPLANTATION; CRITICALLY ILL PATIENT; FATALITY; HEART GRAFT; HEART MUSCLE METABOLISM; HEART OUTPUT; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; MEDICAL PROCEDURES; SURVIVAL RATE;

HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME;

CLENBUTEROL;

EID: 77954916305     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253210362270     Document Type: Article

References (14)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association ; 2000.
2. O'Connell JB, Birstow MR Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994 ; 13: S107 - S112
3. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997 ; 134: 44-54.
4. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001 ; 345: 1435-1443.
5. Miller LW, Pagani FD, Russell SD, et al.; the HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007 ; 357: 885-896.
6. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990 ; 81: 1161-1172.
7. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999 ; 79: 215-262.
8. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 ; 346: 1357-1365.
9. Iwanaga Y., Hoshijima M., Gu Y., et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004 ; 113: 727-736.
10. Yacoub MH A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J. 2001 ; 22: 534-540.
11. Starling RC Inducible nitric oxide synthase in severe human heart failure: impact of mechanical unloading. J Am Coll Cardiol. 2005 ; 45: 1425-1427.
12. Birks EJ, Tansley PD, Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 ; 255: 1873-1884.
13. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009 ; 361: 2241-2251.
14. Meyns B., Klotz S., Simon A., et al. Hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol. 2009 ; 54: 79-86.